Lidocaine: Nursing Drug Guide, IV Toxicity & NCLEX Review
IV lidocaine suppresses ventricular ectopy after acute coronary events, but the same molecule that stabilizes rhythm can cause seizures, respiratory depression, and cardiovascular collapse when bolus rate, hourly totals, or infusion duration are wrong—continuous ECG monitoring and early toxicity recognition are non-negotiable.
IV lidocaine has a narrow therapeutic window. Prescribing information requires continuous ECG monitoring, immediately available resuscitative equipment, and reassessment at the earliest signs of toxicity. CNS effects (drowsiness, tinnitus, perioral numbness → seizures → respiratory arrest) and cardiovascular depression (bradycardia, hypotension, widened QRS, cardiac arrest) can occur with excessive bolus rate, cumulative dose, or prolonged infusion. No more than 200–300 mg IV per hour; bolus only at approximately 25–50 mg/min using approved 5 mL syringe sizes.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every IV dose: confirm indication, contraindications, and continuous telemetry; give bolus only at labeled rate using 5 mL (50 or 100 mg) syringes; cap hourly totals at 200–300 mg; start maintenance at 1–4 mg/min and stop or reduce at the first drowsiness, tinnitus, hypotension, or QRS widening. The same drug name appears on cardiac syringes and local-anesthetic vials—verify concentration, route, and indication every time.
Most common brand names
IV lidocaine hydrochloride is available generically and under trade names that vary by country and concentration. The same active ingredient is also supplied as topical, local infiltration, and regional anesthesia products—verify route, concentration, and indication on every vial or syringe.
Common names: Xylocaine, lignocaine (international spelling). Cardiac IV syringes are often 50 mg/5 mL or 100 mg/5 mL (10–20 mg/mL). Do not confuse cardiac antiarrhythmic syringes with dilute local-anesthetic bags or multidose vials used for procedures.
Why we give it — Indications
Prescribing information for IV lidocaine hydrochloride focuses on ventricular arrhythmias—especially premature ventricular contractions and ventricular tachycardia associated with acute myocardial infarction, digitalis toxicity, or cardiac manipulation during surgery. It is not first-line for stable supraventricular rhythms such as uncomplicated atrial fibrillation.
| Use | Detail |
|---|---|
| Ventricular arrhythmias | Control of PVCs and VT, including after heart attack or during cardiac surgery per labeling |
| Digitalis toxicity | Ventricular arrhythmias when digoxin toxicity is suspected—coordinate with prescriber and pharmacist |
| Continuous monitoring required | Labeling requires continuous ECG monitoring, immediately available resuscitative equipment, and personnel trained in cardiac emergencies |
| Not routine for | Asymptomatic PVCs without hemodynamic compromise, rapid heart rate from non-ventricular causes alone, or prophylaxis without documented ventricular arrhythmia |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Lidocaine is a class Ib antiarrhythmic and amide local anesthetic. It blocks fast sodium channels, shortens action potential duration and refractory period in ventricular tissue, and preferentially suppresses ectopic activity in ischemic or depolarized myocardium. At antiarrhythmic plasma concentrations it can depress automaticity and conduction; at higher levels the same sodium-channel block produces dose-related CNS toxicity (drowsiness, seizures) and cardiovascular depression (bradycardia, hypotension, widened QRS, cardiac arrest). Hepatic metabolism is the primary elimination route; toxicity risk rises when infusion continues after bolus loading without reassessment.
Dosing overview
Institutional protocols and product concentrations may vary. Always verify the specific product label, syringe size, and pharmacy preparation before administration.
IV antiarrhythmic dosing (labeling summary)
| Phase | Dose | Administration rate (labeling) |
|---|---|---|
| Initial bolus | 50–100 mg IV | Approximately 25–50 mg/min; use only approved 5 mL syringes (50 or 100 mg) |
| Repeat bolus | 50–100 mg if needed | May repeat every 5 minutes; do not exceed hourly maximum |
| Hourly maximum | 200–300 mg total IV | No more than 200–300 mg lidocaine hydrochloride during any one-hour period |
| Maintenance infusion | 1–4 mg/min | Start after bolus; reduce or stop at earliest signs of toxicity; reassess need frequently |
On a small screen, swipe or scroll sideways to see the full table.
Renal impairment: Dialysis is of negligible value in acute overdosage; dose adjustment for renal failure is not specified in the reviewed IV labeling for routine use.
Hepatic impairment: Reduce maintenance infusion rate; toxicity may occur at lower total doses because of reduced clearance—consult prescriber/pharmacist.
Missed dose: Not applicable to continuous infusion; if infusion stopped for toxicity, do not restart without new prescriber order and reassessment.
Before you give it — Safety check
Pretreatment checks
- Confirm documented ventricular arrhythmia indication; review rhythm strips and continuous telemetry
- Verify continuous ECG monitoring, defibrillator access, and staff trained in advanced cardiac life support
- Review allergy history for amide local anesthetics (lidocaine, bupivacaine, mepivacaine, etidocaine, prilocaine)
- Perform medication reconciliation—count prior boluses and infusion rate toward the 200–300 mg/hour cap
- Assess for high-grade block, Stokes-Adams syndrome, or Wolff-Parkinson-White pattern on baseline tracing
Contraindications
- Known hypersensitivity to amide-type local anesthetics
- Stokes-Adams syndrome (syncope from sudden inadequate cerebral perfusion with fainting)
- Wolff-Parkinson-White syndrome
- Severe degrees of sinoatrial, atrioventricular, or intraventricular block without an artificial pacemaker
Important interactions and cautions
| Drug / factor | Effect | Nursing action |
|---|---|---|
| Other antiarrhythmics / CNS depressants | Additive CNS and cardiac depression | Lower infusion rate; heightened toxicity surveillance |
| Digoxin | Arrhythmia context may be toxicity—lidocaine does not reverse digoxin | Notify prescriber; monitor potassium and digoxin level per protocol |
| Beta-blockers, calcium channel blockers | Increased risk of bradycardia and hypotension | Continuous blood pressure and rhythm monitoring |
| Hepatic disease | Reduced clearance; higher plasma levels | Slower infusion; review liver function tests if available |
On a small screen, swipe or scroll sideways to see the full table.
Administration
IV bolus: Administer 50–100 mg at approximately 25–50 mg/min under continuous ECG monitoring—typically 2–4 minutes per bolus using a 5 mL syringe. This is a controlled bolus, not an unregulated IV push. A second bolus may follow after five minutes if arrhythmia persists and hourly total remains within limits.
IV infusion: Maintenance 1–4 mg/min via infusion pump after bolus. Reassess at the earliest signs of toxicity; many protocols taper or stop within 24–48 hours if rhythm stabilizes.
- Independent double-check: drug name, concentration (mg/mL), bolus rate, cumulative dose in the last hour, and pump rate in mg/min
- Use only syringes and concentrations approved for antiarrhythmic IV bolus per product labeling
- Document start/stop times, bolus doses, infusion rate changes, and patient symptoms during administration
Rapid bolus, wrong syringe concentration, and pump programmed in mL/hr instead of mg/min are common causes of seizures and cardiovascular collapse. Follow high-alert medication administration and IV infusion pump setup verification; never exceed 200–300 mg in one hour.
Expected therapeutic response
- Reduction in frequency or termination of ventricular ectopy or VT on telemetry
- Improved perfusion when arrhythmia was hemodynamically compromising—blood pressure and mental status stable
- Absence of early toxicity signs (drowsiness, tinnitus, perioral numbness) during and after bolus
- Maintenance infusion at lowest effective rate—ongoing need reassessed at each shift handoff
Red flags — Stop and act
Stop or reduce lidocaine and escalate immediately when CNS or cardiovascular toxicity appears—effects can progress rapidly to seizures, respiratory arrest, and cardiac arrest.
- Early CNS toxicity: dizziness, tinnitus, blurred vision, drowsiness, perioral numbness, tremors
- Advanced CNS toxicity: confusion, seizures, unconsciousness, respiratory depression or arrest
- Cardiovascular toxicity: bradycardia, hypotension, widened QRS, cardiovascular collapse, cardiac arrest
- Hypersensitivity: urticaria, bronchospasm, or anaphylaxis to amide anesthetic
- Order exceeds labeling limits (bolus faster than ~25–50 mg/min, or >200–300 mg IV within one hour)
Adverse effects
| Adverse effect | Notes (labeling) | Nursing response |
|---|---|---|
| CNS toxicity | Drowsiness, tinnitus, visual disturbance, tremors, seizures, respiratory depression/arrest; more likely with rapid bolus or high cumulative dose | Stop or reduce infusion; airway support; notify prescriber; anticonvulsants per protocol if seizures persist |
| Cardiovascular depression | Bradycardia, hypotension, conduction block, cardiac arrest | Stop drug; hemodynamic support and ACLS per protocol |
| Allergic reactions | Urticaria, angioedema, anaphylactoid reactions | Stop permanently; treat hypersensitivity per protocol |
| Proarrhythmia | May worsen conduction in susceptible patients | Continuous telemetry; hold if new high-grade block |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Overdose usually follows excessive bolus rate, repeated boluses without hourly accounting, or maintenance infusion continued despite early toxicity. Plasma levels above approximately 6 mcg free base/mL correlate with increasing objective toxicity per labeling.
Management (labeling)
- Discontinue lidocaine immediately
- Airway and ventilation support; oxygen as indicated
- Seizures: small IV doses of benzodiazepines or ultrashort-acting barbiturates if seizures persist
- Circulatory depression: IV fluids and vasopressors as indicated
- Cardiac arrest: standard cardiopulmonary resuscitation
Antidote: No specific antidote is listed in the reviewed prescribing information. Dialysis is of negligible value in acute lidocaine overdosage.
Contact local poison control or medical toxicology services for overdose guidance per facility protocol and local emergency guidance.
Look-alike / sound-alike and error prevention
- Lidocaine cardiac syringe vs local-anesthetic vial—same drug name, different concentrations and indications; verify antiarrhythmic IV vs infiltration/regional product
- Lidocaine vs lignocaine—same molecule; still verify route and dose
- IV push vs controlled bolus—50–100 mg must run over ~2–4 minutes at 25–50 mg/min, not instantaneous push
- mg/min vs mL/hr pump programming—most common infusion error; pharmacy should clarify concentration
- Hourly dose accumulation—multiple 100 mg boluses plus infusion can exceed 200–300 mg/hour without a running total
- Lidocaine treatment order vs telemetry-only order—ensure antiarrhythmic therapy is not confused with monitoring-only orders on busy units
High-risk populations
| Population | Considerations |
|---|---|
| Older adults | Reduced hepatic clearance; lower infusion rates and careful bolus administration |
| Hepatic impairment | Higher plasma levels at standard doses—reduce maintenance rate; watch for prolonged toxicity |
| Heart failure / shock | Hypotension and perfusion compromise worsen with CV depression; cautious bolus and infusion |
| Conduction disease | Contraindicated in severe block without pacemaker; heightened bradycardia risk |
| Pregnancy / lactation | Use only if clearly needed; crosses placenta—follow obstetric and neonatal monitoring per prescriber |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Continuous cardiac rhythm via telemetry and ECG recording during bolus and infusion
- Neurologic status every 15–30 minutes during active therapy—drowsiness, speech changes, tremors, perioral numbness
- Respiratory rate and oxygenation if sedation or seizure risk
- Cumulative IV dose in the rolling one-hour window (bolus + infusion contribution)
- Hepatic function in prolonged therapy or suspected toxicity
Document
- Indication, bolus dose, administration rate/duration, infusion rate (mg/min), and hourly running total
- Telemetry rhythm before and after bolus; prescriber notification for toxicity or inadequate response
- Patient education on reporting dizziness, ringing ears, numbness, or confusion immediately
Patient teaching
- Report dizziness, ringing in the ears, lip or tongue numbness, blurred vision, confusion, or unusual drowsiness immediately—these may be early toxicity
- Stay on telemetry and ask before getting out of bed unassisted if you feel lightheaded
- This is a temporary IV heart medication—not the same as numbing medicine for procedures; do not request extra doses
- Tell every clinician you received lidocaine before new medicines, especially other heart or sedating drugs
- Understand that therapy will stop or slow if your rhythm improves or if side effects appear
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known hypersensitivity to amide local anesthetics
- Stokes-Adams syndrome, Wolff-Parkinson-White syndrome, or severe sinoatrial, AV, or intraventricular block without functioning pacemaker
- Any early CNS toxicity (drowsiness, tinnitus, perioral numbness, tremors) or seizures
- Cardiovascular collapse, symptomatic bradycardia, or widening QRS with hypotension
- Order would exceed 200–300 mg IV in one hour or bolus faster than approximately 25–50 mg/min
- Unclear indication, wrong product/concentration, or pump rate that does not match mg/min order
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Bolus clock | Use a timer for 50–100 mg over 2–4 minutes—if finished in seconds, rate was too fast |
| Hourly tally | Whiteboard or EMR running total: bolus mg + (mg/min × minutes) toward 200–300 mg cap |
| Pump units | Confirm mg/min, not mL/hr; verify concentration with pharmacy before start |
| After cardioversion | Reassess need for infusion—many patients taper within 24 h if rhythm stable |
| Commonly missed | Second bolus at 5 min without adding first bolus to hourly total; continuing infusion after perioral numbness |
| Ask pharmacy when | Concentration change, hepatic dosing, or transition to oral heart arrhythmia therapy |
On a small screen, swipe or scroll sideways to see the full table.
Clinical practice integration and workflow
IV lidocaine is a short-term rescue drug for ventricular arrhythmias—not maintenance oral therapy. Nursing safety centers on bolus rate control, hourly dose accounting, and stopping at the first toxicity cue while telemetry remains continuous.
1. Check-before-you-give protocol
- Right patient, drug, concentration, dose, route, and documented ventricular arrhythmia indication
- Contraindications ruled out (amide allergy, Stokes-Adams, WPW, severe block without pacemaker)
- Telemetry active; bolus rate plan 25–50 mg/min; hourly total under 200–300 mg
- Independent double-check with second nurse for bolus and pump programming
2. High-alert and safety badge
High-alert IV antiarrhythmic — CNS/CV toxicity from rate and dose errorsMany facilities treat IV lidocaine as high-alert because rapid bolus, infusion programming errors, and cumulative hourly overdose can cause seizures and cardiac arrest within minutes.
3. Clinical workflow: hold and question rules
- Perioral numbness or drowsiness during bolus: stop further lidocaine and notify prescriber before any repeat bolus
- Order written as “IV push lidocaine 100 mg now”: clarify controlled bolus rate—do not administer instant push
- Infusion running 4 mg/min with rising sedation: reduce or hold and reassess—do not wait for seizure
4. Critical teach-back questions
- “What sensations should you report right away?” (Ringing ears, lip numbness, dizziness, confusion.)
- “Why must you stay on the monitor?” (Drug can worsen heart rhythm or cause dangerous slowing; team watches ECG continuously.)
5. Care coordination
Cardiology / electrophysiology: Rhythm management plan, need for repeat bolus, transition off infusion, device/pacing issues
Pharmacist: Concentration verification, hourly dose cap, hepatic dosing, interaction review with digoxin and other antiarrhythmics
🧠 Quick mental checklist
- Is telemetry continuous and is this a true ventricular indication?
- How many milligrams were given in the last 60 minutes (bolus + infusion)?
- Will this bolus run at 25–50 mg/min—not IV push?
- Any perioral numbness, tinnitus, drowsiness, or QRS widening?
- Is the pump set in mg/min with the correct concentration?
Lidocaine NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for lidocaine with a tabbed coronary-care case (MAR, labs, vitals, nursing notes), then priority action, toxicity cue recognition, dose-trend interpretation, matrix urgency sorting, infusion-error judgment, and bolus-rate cloze—recognise cues → analyse → prioritise → act → evaluate outcomes (symptom resolution vs ongoing toxicity vs pump safety).
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Lidocaine 100 mg IV bolus — given 0912 (RN notes “pushed over ~30 seconds”)
- Lidocaine infusion 3 mg/min — started 0915; pump shows 45 mL/hr (concentration 4 mg/mL per pharmacy label)
- Second lidocaine 50 mg IV bolus ordered PRN VT — not yet given
- Heparin infusion per ACS protocol — running
- Admission: K+ 4.1 mEq/L; Mg2+ 2.0 mg/dL; AST 32 U/L, ALT 28 U/L
- Today 0945: K+ 3.8 mEq/L; Mg2+ 1.9 mg/dL; no lidocaine level drawn
- Telemetry: frequent PVCs decreasing after bolus; QRS 96 ms (was 88 ms pre-bolus)
- 0940: BP 102/64, HR 88, RR 18, SpO2 96% on room air
- Patient reports ringing in ears and “numb lips”; drowsy but arousable
- 0900: Post–STEMI day 1; ventricular ectopy on monitor; prescriber ordered lidocaine bolus then infusion
- 0912: Bolus administered by new float RN—experienced RN reviewing rate after patient complaint
- 0942: Hourly lidocaine total ~118 mg bolus + ~81 mg infusion (3 mg/min × 27 min) → approaching 200 mg in first hour
Answer key & rationale
Frequently asked questions
What must nurses check before giving IV lidocaine?
Confirm a ventricular arrhythmia indication, verify the patient is not contraindicated (including Stokes-Adams syndrome, Wolff-Parkinson-White syndrome, or severe heart block without a pacemaker), review allergies to amide local anesthetics, ensure continuous ECG monitoring is available, and confirm resuscitative equipment and trained personnel are immediately accessible per labeling.
When should a nurse hold lidocaine and notify the prescriber or pharmacist?
Hold for known hypersensitivity to amide local anesthetics; Stokes-Adams syndrome, Wolff-Parkinson-White syndrome, or severe sinoatrial, atrioventricular, or intraventricular block without an artificial pacemaker; early CNS toxicity (drowsiness, tinnitus, confusion, tremors); widening QRS or excessive cardiac depression on ECG; hypotension or cardiovascular collapse; seizures or respiratory depression; or orders that exceed labeling limits such as more than 200–300 mg IV within one hour or bolus faster than approximately 25–50 mg/min.
What is the maximum IV lidocaine dose per hour?
Prescribing information states no more than 200 to 300 mg of lidocaine hydrochloride should be administered during a one-hour period. Bolus is usually 50 to 100 mg at approximately 25 to 50 mg/min under ECG monitoring, with a possible second bolus after five minutes if needed; continuous infusion is typically 1 to 4 mg/min and should be reassessed at the earliest signs of toxicity.
What are early signs of lidocaine toxicity nurses should recognize?
Central nervous system toxicity may begin with lightheadedness, dizziness, tinnitus, blurred vision, drowsiness, or perioral numbness and can progress to tremors, seizures, unconsciousness, and respiratory depression or arrest. Cardiovascular toxicity includes bradycardia, hypotension, and cardiovascular collapse leading to cardiac arrest. Objective adverse effects become increasingly apparent with plasma levels above approximately 6 mcg free base per mL per labeling.
Is there an antidote for lidocaine overdose?
No specific antidote is listed in the reviewed prescribing information. Management focuses on airway and ventilation support, small intravenous anticonvulsant doses such as benzodiazepines or ultrashort-acting barbiturates for persistent seizures, vasopressors for circulatory depression, and standard cardiopulmonary resuscitation if cardiac arrest occurs. Dialysis is of negligible value for acute lidocaine overdosage.
References
- U.S. National Library of Medicine. LIDOCAINE HYDROCHLORIDE injection — Full prescribing information. DailyMed (setid ad1ef0a8-88db-4648-c098-d009eaeb4e5b).https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad1ef0a8-88db-4648-c098-d009eaeb4e5b
- U.S. National Library of Medicine. LIDOCAINE HYDROCHLORIDE injection, solution — Full prescribing information. DailyMed (setid f1b26274-a55e-4321-b96c-ce0df830f205).https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1b26274-a55e-4321-b96c-ce0df830f205
- Drugs and Lactation Database (LactMed). Lidocaine. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK501230/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.